老年丹麦人他汀类药物使用:起始4年内停药的相关因素
年龄增长与停药风险升高相关,二级预防及合并心血管药物使用与停药风险降低相关。
要点
- 70岁及以上新起始他汀者4年总体停药率为32%,第1年停药率13%。
- 年龄越大停药风险越高,>95岁与70-74岁相比4年调整OR为3.94。
- 二级预防较一级预防停药风险更低,1年调整OR为0.74。
核心结论
- 老年新起始他汀者4年内停药主要与年龄增长相关,合并症、多重用药、二级预防及合并心血管药物使用也可能影响停药。
主要发现
- 第1年13%停药,第2年和第4年分别另有12%和13%停药,4年总体停药率为32%。
- 年龄增长与各时间点停药相关:>95岁 vs 70-74岁,1年调整OR=2.06(95%CI 1.35-3.16),4年调整OR=3.94(95%CI 1.83-8.49)。
- 较高合并症评分和使用超过10种药物与停药呈 modest 关联。
- 二级预防较一级预防停药风险更低:1年调整OR=0.74(95%CI 0.65-0.83),4年调整OR=0.83(95%CI 0.72-0.95),合并心血管治疗亦与停药风险降低相关。
- 2008至2015年间,早期停药者年度比例在一级预防为14%-17%,二级预防为9%-12%。
关键数值与推荐
- 4年总体停药率32%,第1年13%,第2年12%,第4年13%。
- 年龄>95岁 vs 70-74岁:1年调整OR=2.06(95%CI 1.35-3.16),4年调整OR=3.94(95%CI 1.83-8.49)。
- 二级预防 vs 一级预防:1年调整OR=0.74(95%CI 0.65-0.83),4年调整OR=0.83(95%CI 0.72-0.95)。
临床怎么用
- 对高龄、合并症多、多重用药的老年他汀使用者,应关注停药风险并加强随访。
- 二级预防患者停药风险较低,但仍需个体化评估继续治疗的获益与风险。
局限性
- 原文未报告停药的具体原因,需未来研究澄清。
- 原文未报告研究的具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Use of statins is considerable among older persons. We investigated factors associated with statin discontinuation in new statin users aged 70 years or older within the first 4 years of use. DESIGN: Register-based descriptive drug utilization study using data from 2008 to 2016. POPULATION/SETTING: All Danish persons, aged 70 years or older, initiating statin treatment. MEASUREMENTS: Rates and predictors of statin discontinuation after 1 year (early), 2 years, and 4 years. Predictors of discontinuation were estimated using logistic regression. RESULTS: We included 83 788 statin initiators. At 1 year, 13% had discontinued their treatment, while another 12% and 13% discontinued after 2 and 4 years, respectively. The overall discontinuation rate over 4 years was 32%. Increasing age was associated with discontinuation at all time points (adjusted odds ratio [OR] = 2.06 [95% confidence interval {CI} = 1.35-3.16] at 1 year, adjusted OR = 3.94 [95% CI, 1.83-8.49] at 4 years, comparing those aged >95 years to those aged 70-74 years). Further, higher comorbidity scores and use of more than 10 medications were modestly associated with discontinuation. Use of statins for secondary prevention was associated with decreased odds of discontinuation compared to primary prevention at 1 year (adjusted OR = 0.74; 95% CI, 0.65-0.83) and at 4 years (adjusted OR = 0.83; 95% CI, 0.72-0.95), along with concomitant use of cardiovascular (CV) therapies. The annual proportion of early discontinuers ranged from 14% to 17% for primary prevention and from 9% to 12% for secondary prevention between 2008 and 2015. DISCUSSION: Statin discontinuation within the first 4 years after initiation appeared to be influenced most strongly by age, and may also be influenced by comorbidity, polypharmacy, use for secondary prevention, and concomitant CV medication use. Future research should clarify reasons for, and discussions about, statin discontinuation and initiation among older persons, to provide additional insight on this topic. J Am Geriatr Soc 67:2050-2057, 2019.
引用
- Thompson W, Jarbøl DE, Haastrup P, et al. Statins in Older Danes: Factors Associated With Discontinuation Over the First 4 Years of Use. J Am Geriatr Soc. 2019. PMID: 31335968. doi:10.1111/jgs.16073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。